Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | TARBP2 | Q15633 | 3/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192579 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MLYCDTARBP2CACNA1FCACNA1D | |
| SCHEMBL10627069 | 0.86 | TARBP2 (0.42) | ALDH1A1MLYCDTARBP2CACNA1FCACNA1D | |
| SCHEMBL12416429 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MLYCDTARBP2CACNA1FCACNA1D | |
| SCHEMBL5431807 | 0.81 | NPSR1 (0.45) | ALDH1A1KDM4EPOLB | |
| SCHEMBL23596007 | 0.79 | TSHR (0.50) | ALDH1A1HTTKDM4EPKM | |
| SCHEMBL766573 | 0.79 | TARBP2 (0.42) | ALDH1A1MLYCDTARBP2CACNA1FCACNA1D | |
| SCHEMBL436752 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MLYCDTARBP2CACNA1FCACNA1D | |
| SCHEMBL23971429 | 0.77 | CYP2C9 (0.40) | ALDH1A1MLYCDKDM4E | |
| SCHEMBL2733993 | 0.77 | ALDH1A1 (0.57) | ALDH1A1MLYCDTARBP2CACNA1FCACNA1D | |
| SCHEMBL353667 | 0.77 | ALDH1A1 (0.57) | ALDH1A1MLYCDTARBP2CACNA1FCACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024652-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8557815-B2 | Substituted triazolophthalazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110172235-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172235-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | GPR55, HTR5A, GRK5 | ALDH1A1 2452/4885MLYCD 4513/4885TARBP2 3784/4885 |
| US-20140024652-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | GPR55, HTR5A, GRK5 | ALDH1A1 2452/4885MLYCD 4513/4885TARBP2 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.